[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529514":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":43,"locations":51,"responsibleParty":64,"collaborators":32,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":32,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":32,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":32,"overallStatus":54,"whyStopped":32,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Hanmi Pharmaceutical Company Limited","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental1","EXPERIMENTAL","Take HGP2102-1 once daily for 4 weeks orally, and then take HGP2102-2 once daily for 6 weeks orally.",[13,14],"Drug: HGP2102-1","Drug: HGP2102-2",{"label":16,"type":10,"description":17,"interventionNames":18},"Experimental2","Take HGP2102-1 once daily for 10 weeks orally.",[13],{"label":20,"type":21,"description":22,"interventionNames":23},"Active Comparator","ACTIVE_COMPARATOR","Take RLD2209-1 once daily for 4 weeks orally, and then take RLD2209-2 once daily for 6 weeks orally.",[24,25],"Drug: RLD2209-1","Drug: RLD2209-2",[27,33,36,40],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","HGP2102-1","Test drug",[9,16],null,{"type":28,"name":34,"description":30,"armGroupLabels":35,"otherNames":32},"HGP2102-2",[9],{"type":28,"name":37,"description":38,"armGroupLabels":39,"otherNames":32},"RLD2209-1","Control drug",[20],{"type":28,"name":41,"description":38,"armGroupLabels":42,"otherNames":32},"RLD2209-2",[20],[44,49],{"name":45,"role":46,"phone":47,"phoneExt":32,"email":48},"Na Young Kim","CONTACT","82-2-410-9165","skyko7@hanmi.co.kr",{"name":50,"role":46,"phone":32,"phoneExt":32,"email":32},"Seok Min Kang, Ph.D",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":32,"cosmosGeoPoint":32,"geoPoint":32,"contacts":59},"Sevrance hosptal","RECRUITING","Seodaemun-gu","Seoul","03722","South Korea",[60],{"name":61,"role":46,"phone":62,"phoneExt":32,"email":63},"Seokmin Kang, M.D., Ph.D.","82-2-2228-8450","smkang@yuhs.ac",{"type":65,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100529514","phase-3-a-study-to-evaluate-efficacy-and-safety-of-hgp2102-in-essential-hypertension-patients-100529514",false,"NCT06174766","A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients","A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension","Inclusion Criteria:\n\n1. Subjects whose clinic blood pressure measured in visit 1 corresponds to the following conditions\n\n   * sitSBP\\\u003C180 mmHg and sitDBP\\\u003C110mg for patients receiving any BP-lowering drug within 1 month prior to Visit 1\n   * 140mmHG≤sitSBP\\\u003C180mmHg and 60mmHg≤sitDBP\\\u003C110mmHg\n2. Subjects whose clinic and ambulatory blood pressure measured in visit 2 corresponds to the following conditions\n\n   * 24h-ABPM: 130mmHg≤ SBP \\\u003C170mmHg\n   * clinic BP: 140 mmHg ≤ sitSBP \\\u003C 180 mmHg and 60 mmHg ≤ sitDBP \\\u003C 110 mmHg\n\nExclusion Criteria:\n\n1. Difference between arms greater than 20 mmHg for mean sitSBP or 10mmHg for mean sitDBP at Visit 1\n2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1\n3. Orthostatic hypotension with symptoms within 3 months prior to visit 1\n4. Secondary hypertension patient or suspected to be\n5. Uncontrolled type II diabetes mellitus (HbA1c \\> 9%) or type I diabetes mellitus\n6. Severe heart disease or severe neurovascular disease\n7. Moderate or malignant retinopathy\n8. Severe renal diseases (eGFR\\\u003C30mL\u002Fmin\u002F1.73m2)\n9. Severe or active hepatopathy (AST or ALT ≥ 2 times of normal range)\n10. Hypokalemia or Hyperkalemia (K\\\u003C3.5mmol\u002FL or K ≥ 5.5mmol\u002FL)\n11. Hyponatremia or Hypernatremia (Na\\\u003C135mmol\u002FL or Na ≥ 155mmol\u002FL)\n12. History of malignancy tumor\n13. History of alcohol or drug abuse\n14. Positive to pregnancy test, nursing mother, intention on pregnancy\n15. Considered by investigator as not appropriate to participate in the clinical study with other reason","ALL","19 Years",{"count":76,"type":77},324,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension",[83],"Hypertension","2025-06-08",{"date":86,"type":87},"2025-06-12","ACTUAL",{"date":89,"type":87},"2024-05-10",{"date":91,"type":77},"2026-12-31",{"name":5,"class":6},1]